08:29 AM EDT, 05/13/2024 (MT Newswires) -- Medicenna Therapeutics ( MDNAF ) said the American Society of Clinical Oncology (ASCO) has withdrawn its abstract detailing results from the ABILITY-1 monotherapy dose escalation study with MDNA11, in patients with advanced solid tumors, which had been selected for an oral podium presentation at ASCO's 2024 Annual Meeting.

ASCO's Program Committee had determined that Medicenna had allegedly violated ASCO's "Prior Publication Policy" by previously reporting results at the 2024 Annual Meeting of the American Association of Cancer Research (AACR). No other concerns were raised by the ASCO Program Committee.

Medicenna disagrees with the Committee's decision, saying it did not violate ASCO's Prior Publication Policy. While Medicenna did present results at the AACR, that abstract explicitly referenced a data cut-off date of December 23, 2023, and only on-going interim monotherapy results were presented, whereas the ASCO abstract specified that the results presented would focus on a complete Phase 1 monotherapy data set without a data cut-off date. This complete data set was analyzed and prepared specifically for presentation at ASCO 2024, Medicenna said.

The company will now host a virtual event over the next two to four weeks, where clinical data originally planned for the 2024 ASCO Annual Meeting and that has not previously been presented at any external conference, including AACR, will be presented from the Phase 1/2 ABILITY-1 Study evaluating MDNA11, as both a monotherapy and in combination with pembrolizumab (Keytruda) in patients with advanced or metastatic solid tumors.

The second abstract of the company, offering new data analyses for bizaxofusp (formerly known as MDNA55), a Phase-3 ready immunotherapy for recurrent glioblastoma, will be presented as a poster at the 2024 ASCO Annual Meeting, as was previously announced.

Medicenna shares fell 11% on Friday to $2.47.